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Abstract
Background: Very little is known for the direction or causality of the relationship between lifetime sleep experiences
and in vivo Alzheimer’s disease (AD) pathologies. This study aimed to examine the relationship between sleep
experiences during the young adulthood, midlife, and late-life periods and in vivo cerebral beta-amyloid (Aβ)
deposition and AD signature regional neurodegeneration in cognitively normal (CN) old adults.
Methods: This study included 202 CN old adults who participated in the Korean Brain Aging Study for the
Early Diagnosis and Prediction of Alzheimer’s Disease (KBASE) study. All participants underwent a comprehensive clinical
assessment, [11C] Pittsburgh Compound B positron emission tomography (PET), [18F] Fluorodeoxyglucose-PET,
and magnetic resonance imaging. The quality and duration of sleep were assessed for the following age periods: 20–
30s, 40–50s, and the most recent month. All analyses were adjusted for age, gender, education, apolipoprotein E ε4
status, vascular risk score, Hamilton Depression Rating Scale score, and use of sleep medication.
Results: Bad sleep quality and short sleep duration during midlife were significantly associated with increased
Aβ deposition and AD signature regional hypometabolism, respectively. Although current bad sleep quality appeared
to be associated with increased Aβ accumulation, this association disappeared after controlling for the effects of
midlife sleep quality. Neither the quality nor duration of sleep during young adulthood was related to Aβ
burden or neurodegeneration.
Conclusions: Bad sleep quality during midlife increases pathological Aβ deposition in the brain, while short
sleep duration during the same period accelerates regional hypometabolism.
Keywords: Midlife sleep, Preclinical Alzheimer’s disease, Cerebral amyloid, Neurodegeneration
Background
A number of studies have shown that disturbed sleep
and Alzheimer’s disease (AD) dementia are closely re-
lated [1–3]. Further, experimental evidence suggests that
the relationship between poor sleep and beta-amyloid
(Aβ) accumulation, which is a pathological hallmark of
AD, is bidirectional [4]. For example, Aβ aggregation
disrupts the sleep-wake cycle as well as the diurnal fluc-
tuation of Aβ in mice [5], and conversely, acute sleep
deprivation increases brain Aβ levels and chronic sleep
restriction increased Aβ plaque formation in transgenic
mice [6]. It has also been suggested that AD pathophysi-
ology impairs the sleep-regulating system including
hypocretin and melatonin regulation, and reversely,
hypocretin and melatonin may play an important role in
modulating AD pathophysiology [7].
Several clinical studies based on amyloid positron emis-
sion tomography (PET) imaging have revealed that poorer
self-reported sleep quality is associated with a greater in
vivo Aβ burden in the human brain [8–11], while the
association between self-reported sleep duration and Aβ
deposition is controversial [8, 10–12]. However, all studies
that have investigated this relationship had cross-sectional
designs and merely correlated current sleep experience
with Aβ; thus, they could not provide any clue on the
direction or causality of the relationship. Two translational
human studies partly demonstrated the causal relationship;
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one night of sleep deprivation increased cerebrospinal fluid
(CSF) Aβ42 [13], and slow-wave activity disruption in-
creased CSF Aβ40 [14]. However, they only tested the
acute effect of disrupted sleep, which may differ from the
lifelong effects of poor sleep.
To overcome these limitations, we assessed sleep expe-
riences, including sleep quality and sleep duration, of
cognitively normal (CN) old adults during three periods
of life: young adulthood, midlife, and late-life. Rather
than merely assessing the cross-sectional association be-
tween current sleep and pathology, this information was
used to examine the influences of each lifetime sleep ex-
perience on in vivo cerebral Aβ deposition. In addition,
the associations of lifetime sleep experiences with AD
signature regional neurodegeneration, as measured using
cerebral glucose metabolism and cortical thickness, were
evaluated. Only limited information is available regard-
ing this association [9, 15].
Methods
Participants
The present study was part of the Korean Brain Aging
Study for the Early Diagnosis and Prediction of Alzheimer’s
Disease (KBASE) [16], which is an ongoing prospective co-
hort investigation, and included a total of 202 CN elderly
individuals from the KBASE cohort. The inclusion criteria
were being aged from 60 to 90 years old, a Clinical Demen-
tia Rating score of 0, and no diagnosis of mild cognitive
impairment or dementia. The exclusion criteria were as
follows: the presence of any serious medical, psychiatric, or
neurological disorder that could affect mental functioning;
major sleep disorder other than insomnia disorder (e.g.,
rapid eye movement sleep behavior disorder, obstructive
sleep apnea, and/or restless legs syndrome); the presence
of severe communication problem that would make a
clinical examination or brain scan difficult; contraindica-
tions for a magnetic resonance imaging (MRI) scan; the
absence of a reliable informant; illiteracy; and/or participa-
tion in another clinical trial of sleep treatment.
Clinical assessment
All participants underwent a standardized clinical evalu-
ation conducted by trained psychiatrists which was
based on the KBASE clinical assessment protocol, which
incorporates the Korean version of the Consortium to
Establish a Registry for Alzheimer’s Disease Assessment
Packet (CERAD-K) [17]. The KBASE neuropsychological
assessment protocol that incorporates the CERAD
neuropsychological battery [18] was also given to all par-
ticipants by trained neuropsychologists. The presence of
six vascular risk factors, including hypertension, diabetes,
dyslipidemia, transient ischemic attack, stroke, and coron-
ary artery disease, was systematically evaluated; a vascular
risk score (VRS) was calculated as the total number of the
vascular risk factors and reported as a percentage [19].
Depressive symptoms were measured using the Hamilton
Depression Rating Scale (HDRS) [20].
Assessment of sleep experiences
All participants were systematically interviewed by
trained nurses using a structured interview form to de-
termine past average sleep duration and subjective sleep
quality during the following lifetime periods: 20–39
(young adulthood) and 40–59 (midlife) years. The par-
ticipants also completed the Pittsburgh Sleep Quality
Index (PSQI) [21]; of the 18 PSQI items, items assessing
sleep duration (item #4) and subjective sleep quality
(item #18) were used for the evaluation of current (i.e.,
late-life) sleep experiences. For all past (i.e., young adult-
hood and midlife) and current sleep experiences, sleep
duration was reported as the mean hour of sleep and
subjective sleep quality was rated on a 4-point scale
(“very good,” “fairly good,” “fairly bad,” and “very bad”).
Information about current and past sleep disorders and
the current use of sleep medication was also obtained
through the structured interview and a review of medical
records by trained nurses.
Neuroimaging evaluation
Aβ deposition
All participants underwent simultaneous three-dimensional
(3D) [11C] Pittsburgh compound B (PiB) PET and 3D T1-
weighted MRI scans using a 3.0-T Biograph mMR (PET-
MR) scanner (Siemens; Washington DC, USA); the details
of the PiB-PET and MRI acquisition and preprocessing
have been described in a previous report from our research
group [22]. The automated anatomical labeling algorithm
[23] and a region-combining method [24] were applied to
determine the region of interests (ROIs) to characterize
11C-PiB retention levels in the frontal, lateral parietal, pos-
terior cingulate-precuneus, and lateral temporal regions of
the brain. The standardized uptake value ratio (SUVR) for
each ROI was calculated by dividing the mean value for all
voxels within each ROI by the mean cerebellar uptake value
[25]. Participants were classified as Aβ positive if the SUVR
was > 1.4 in at least one of the four ROIs or as Aβ negative
if the SUVR each of the four ROIs was ≤ 1.4 [24, 26]. A glo-
bal Aβ retention value was generated by dividing the mean
value for all voxels of the global cortical ROI by the mean
cerebellar uptake value in the same image [24, 25, 27].
AD signature region neurodegeneration
Participants also underwent 3D [18F] fluorodeoxyglucose
(FDG) PET imaging using the same PET-MR machine
described above. The details of the FDG-PET image
acquisition and preprocessing have been described in a
previous report from our research group [22]. Voxel-
weighted mean SUVRs were extracted from AD signature
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FDG ROIs known to be sensitive to the metabolic changes
associated with AD [27, 28], including the angular gyri,
posterior cingulate cortex, and inferior temporal gyri. AD
signature region cerebral glucose metabolism (AD-CM)
was defined as the voxel-weighted mean SUVR of the
AD signature FDG ROIs. AD signature region cortical
thickness (AD-CT) on the MRI scans was defined as
the mean cortical thickness values obtained from AD
signature regions, including the entorhinal, inferior
temporal, and middle temporal cortices and fusiform
gyrus, as previously described [27]. AD signature neu-
rodegeneration (AD-ND) positivity was defined as an
AD-CM < 1.386 and/or an AD-CT < 2.666 mm, as de-
scribed in previous studies [27–29].
Apolipoprotein E genotyping
Genomic DNA was extracted from whole blood samples,
and apolipoprotein E (APOE) genotyping was performed
as previously described [30]. APOE ε4 (APOE4) positiv-
ity was coded if at least one ε4 allele was present.
Statistical analyses
For the present analyses, self-reported sleep quality was
originally recorded using a 4-point scale but then was
transformed into a dichotomous variable (“good” or
“bad”) because only a small number of participants re-
ported “very bad” sleep quality. Duration of sleep was
treated as a continuous variable. Multiple logistic regres-
sion analyses were performed to examine the association
between sleep quality (or sleep duration) during each
lifetime period and the rate of Aβ (or AD-ND) positivity
after controlling for age, gender, education, APOE4,
VRS, current use of sleeping pills, and HDRS score. In
addition, multiple linear regression analyses that treated
global Aβ deposition and neurodegeneration biomarkers
as dependent variables were conducted after controlling
for the same covariates used in the logistic regression
analyses. Global Aβ deposition and AD-CT were natural
log-transformed to achieve a normal distribution. In the
event that a sleep variable was significantly related to an
imaging variable, the moderating effects of APOE4 were
further explored by also including a sleep variable ×
APOE4 interaction term as an independent variable after
controlling for the same covariates. All statistical ana-
lyses were conducted using IBM SPSS Statistics 21, and
p values < 0.05 were considered to indicate statistical
significance.
Results
Demographics and clinical characteristics
The characteristics of the study participants are presented
in Table 1. After the sleep quality based on the 4-point
scale was transformed into a dichotomous variable (“good”
or “bad”), the proportions of bad sleep were 6.4%, 10.4%,
and 11.9% for the young adulthood, midlife, and current
lifetime periods, respectively. Although the percentage of
bad sleepers increased with age, the differences were not
statistically significant (chi-square value = 2.496, p =
0.287). The mean durations of sleep were 6.83, 6.65, and
6.42 h for each lifetime period; these differences were
significant according to an analysis of variance (ANOVA;
F = 6.048, df = 2, p = 0.003).
Associations between sleep experiences and Aβ
deposition
Multiple logistic regression analyses revealed that mid-
life and current sleep qualities were significantly associ-
ated with Aβ positivity whereas young adulthood sleep
quality was not (Table 2). The bad sleep qualities in the
midlife and current periods were associated with 4.636-
fold and 4.194-fold increases in the probability of Aβ
positivity, respectively. Additional analyses including
the sleep quality × APOE4 interaction term revealed
that the interaction term was not significant for either
the midlife or current lifetime period. Sleep duration in
any lifetime periods was not related to Aβ positivity. As
shown in Table 2, the multiple linear regression ana-
lyses revealed that midlife sleep quality had a significant
Table 1 Demographics and clinical characteristics of study
subjects (n = 202)
Age, years 71.07 (6.74)
Female 102 (50.5%)
Education level, years 11.51 (4.77)
APOE4 carrier 37 (18.3%)
Vascular risk score, % 17.49 (15.84)
HDRS 0.74 (1.51)
Current use of any sleep medication 6 (3.0%)
Bad sleep quality (bad + very bad)




Young adulthood 6.83 (1.11)
Midlife 6.65 (1.18)
Current 6.42 (1.31)
Aβ positive 33 (16.3%)
Global Aβ deposition 1.20 (0.25)
AD-ND positive 112 (55.4%)
AD-CM 1.41 (0.12)
AD-CT, mm 2.84 (0.18)
Data are presented as mean (standard deviation) or number (%)
APOE4 apolipoprotein E ε4, HDRS Hamilton Depression Rating Score, Aβ beta-
amyloid, AD-ND Alzheimer’s disease signature region neurodegeneration, AD-
CM Alzheimer disease signature region cerebral glucose metabolism, AD-CT
Alzheimer’s disease signature region cortical thickness
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association with global Aβ deposition. By contrast,
there were no significant relationships between another
lifetime sleep quality and global Aβ deposition or be-
tween sleep duration in any lifetime periods and Aβ
deposition.
Table 3 shows the results from the multiple logistic re-
gression analysis that included both midlife and current
sleep qualities as independent variables and Aβ positivity
as a dependent variable. Midlife sleep quality was signifi-
cantly associated with Aβ positivity whereas late-life sleep
quality was not.
Associations between sleep experiences and AD signature
neurodegeneration
Multiple logistic regression analyses revealed that sleep
quality in any lifetime periods was not associated with
AD-ND positivity (Table 4). However, shorter sleep dur-
ation in midlife, but not the other lifetime periods, was
significantly associated with a higher AD-ND positivity
rate. There were no interaction effects of midlife sleep
duration and APOE4 on AD-ND positivity. These results
were very similar, even after controlling for global Aβ re-
tention as an additional covariate.
Multiple linear regression analyses revealed that bad
sleep quality in any lifetime periods was not associated
with either AD-CM or AD-CT (Table 5). In terms of
sleep duration, shorter duration in midlife, but not any
other lifetime periods, was significantly associated with
decreased AD-CM. Additional analyses did not reveal
an interaction between midlife sleep duration and
APOE4 and showed that sleep duration in any lifetime
periods was not related to AD-CT. Similar results were
obtained after further adjustment for global Aβ depos-
ition (Additional file 1: Table S1).
Discussion
In CN elderly individuals, bad sleep quality and shorter
sleep duration during the midlife period were signifi-
cantly associated with higher levels of Aβ deposition and
increased AD-ND, respectively. Although current bad
sleep quality appeared to be associated with increased
Aβ accumulation, this relationship disappeared after
controlling for the effects of midlife sleep quality. Nei-
ther sleep quality nor duration of sleep during young
adulthood was related to Aβ burden or neurodegenera-
tion. To the best of our knowledge, this study is the first
to reveal the associations of sleep experience in different
lifetime periods with cerebral Aβ accumulation and
neurodegeneration.
Based on the temporal order of the lifetime periods, the
finding that there was a significant association between
bad sleep quality during the 40–50 years of age period and
increased late-life Aβ deposition suggests that midlife
sleep disturbances may contribute to pathological Aβ
deposition. Similarly, the significant association between
short sleep duration in midlife and increased AD-ND
could also be interpreted as the influence of short sleep
duration during midlife on the acceleration of the neuro-
degenerative process. Although several previous studies
have reported that a greater Aβ burden is associated with
poorer self-reported sleep quality in CN old adults [8–11],
these studies only collected current sleep data at the time
Table 2 Association between lifetime sleep experience and Aβ positivity (or global Aβ deposition)
Sleep quality Sleep duration
Logistic regression Linear regression Logistic regression Linear regression
aOR (95% CI)a p Betab p aOR (95% CI) p Beta p
Young adulthood 1.864 (0.434–8.016) 0.403 0.058 0.401 1.373 (0.913–2.063) 0.128 0.099 0.148
Midlife 4.636 (1.448–14.844) 0.010 0.174 0.012 1.170 (0.804–1.703) 0.412 0.056 0.419
Current 4.194 (1.156–15.218) 0.029 0.134 0.091 0.905 (0.665–1.233) 0.528 − 0.028 0.685
Both logistic and linear regression analyses were adjusted for age, gender, education, APOE4 status, vascular risk score, use of sleep pill, and Hamilton Depression
Rating Score. Global Aβ deposition was natural log-transformed to achieve normal distribution
Aβ beta-amyloid, aOR adjusted odds ratio, CI confidence interval, APOE4 apolipoprotein E ε4
aGood sleep quality was taken as a reference, so aOR represents the likelihood of being Aβ positive for bad sleep quality compared with good one
bPositive beta value means that worse sleep quality is associated with increased Aβ deposition
Table 3 Multiple logistic regression analysis with midlife and
current sleep qualities as independent variables and Aβ
positivity as a dependent variable
Covariates aOR (95% CI) p value
Age 1.112 (1.041–1.188) 0.002
Gender 1.043 (0.424–2.563) 0.927
Education 1.056 (0.954–1.168) 0.292
APOE4 status 3.314 (1.297–8.467) 0.012
Vascular risk score 0.987 (0.960–1.015) 0.357
Use of sleep pill 4.606 (0.715–29.659) 0.108
HDRS 0.833 (0.572–1.212) 0.340
Midlife sleep quality 3.796 (1.117–12.895)a 0.033
Current sleep quality 3.183 (0.793–12.779)a 0.103
Aβ beta-amyloid, aOR adjusted odds ratio, CI confidence interval, APOE4
apolipoprotein E ε4, HDRS Hamilton Depression Rating Scale
aGood sleep quality was taken as a reference, so aOR represents the likelihood
of being Aβ positive for bad sleep quality compared with good one
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of amyloid imaging. Therefore, the results are not able to
provide information regarding the direction of the rela-
tionship between sleep and Aβ deposition. Similar to
previous studies, we found that current sleep quality was
significantly associated with Aβ accumulation when not
considering the effects of the past sleep experience.
However, this difference was no longer significant when
the effects of sleep quality over the preceding midlife
period were considered in the same model. Taken to-
gether, the present results suggest that chronic bad sleep
experiences, particularly poor sleep quality during midlife,
could accelerate cerebral Aβ deposition. However, the
actual influence of current sleep quality on Aβ deposition,
and vice versa, remains unclear. In contrast to the results
for sleep quality, there were no associations between the
past or current sleep duration and Aβ accumulation in the
present study, which is consistent with most previous
reports [10–12, 31]. This null finding can be explained, at
least in part, by the fact that an optimal duration of sleep,
compared to sleep quality, will vary across the lifespan
and from person to person [32].
Several studies have provided clues regarding the
plausible mechanisms that may underlie the influence of
sleep disturbances on cerebral Aβ accumulation. Aβ
levels in the brain interstitial fluid (ISF) are directly
increased by elevations in synaptic activity [33], which
decreases during sleep [34]. Therefore, disturbed sleep
could increase amyloid production via enhancements of
synaptic activity. In terms of Aβ clearance, natural sleep
increases the exchange in cerebrospinal fluid with ISF,
which results in an elevated rate of Aβ clearance [35].
Regarding neurodegeneration, we found that short sleep
duration during midlife was associated with decreased
glucose metabolism in the brain regions that are vulner-
able to AD [27, 28]; this finding remained significant even
after controlling for global Aβ deposition. Evidence from
experimental as well as clinical studies indicates that in-
sufficient sleep, whether it is behavioral or disease-related,
may stimulate appetite and cause disturbances in glucose
metabolism [36]. Moreover, several studies have demon-
strated that higher fasting serum glucose levels [37] or
higher glycated hemoglobin levels [38] in non-diabetic CN
older adults are associated with cerebral hypometabolism
in AD signature brain regions. Furthermore, wakefulness
promotes neurotoxic and oxidative stresses that are
related to neurodegeneration, which increases the risk for
AD [39]. Overall, the present results provide additional in-
sights regarding the manner in which short sleep duration
during the midlife period could contribute to AD-related
cerebral hypometabolism via an amyloid-independent
mechanism.
In contrast to the findings regarding cerebral Aβ de-
position and regional hypometabolism, there were no
significant associations between sleep experiences during
any of the lifetime periods and cortical thickness in the
AD signature regions. Only a few studies have investi-
gated the associations between brain structures and
sleep in healthy individuals. These studies have found
that a reduced volume in the orbitofrontal cortex (OFC)
is linked with increased early morning awakenings [40]
and daytime sleepiness [41]. Furthermore, increased
atrophy in the superior frontal cortex [15] and insular
region [9] is associated with poor sleep quality. In the
Table 4 Multiple logistic regression analyses with AD-ND positivity as a dependent variable
Sleep quality Sleep duration
Model 1 Model 2 Model 1 Model 2
aOR (95% CI)a p aOR (95% CI)a p aOR (95% CI) p aOR (95% CI) p
Young adulthood 1.428 (0.426–4.786) 0.564 1.423 (0.423–4.781) 0.569 0.826 (0.628–1.088) 0.174 0.823 (0.625–1.084) 0.166
Midlife 1.989 (0.714–5.539) 0.188 1.999 (0.708–5.641) 0.191 0.679 (0.516–0.894) 0.006 0.678 (0.514–0.893) 0.006
Current 0.693 (0.236–2.036) 0.504 0.677 (0.227–2.018) 0.484 0.938 (0.745–1.182) 0.588 0.939 (0.745–1.184) 0.594
Model 1: adjusted for age, gender, education, APOE4 status, vascular risk score, use of sleep pill, Hamilton Depression Rating Score. Model 2: adjusted for
covariates of model 1 + global Aβ deposition. Global Aβ deposition was natural log-transformed to achieve normal distribution
AD-ND Alzheimer’s disease signature region neurodegeneration, aOR adjusted odds ratio, CI confidence interval, Aβ beta-amyloid, APOE4 apolipoprotein E ε4
aGood sleep quality was taken as a reference, so aOR represents the likelihood of being AD-ND positive for bad sleep quality compared with good one
Table 5 Multiple linear regression analyses with
neurodegeneration biomarkers as dependent variables
Sleep quality Sleep duration
Betaa p Betaa p
Dependent variable: AD-CM
Young adulthood 0.011 0.880 0.135 0.054
Midlife − 0.058 0.418 0.173 0.015
Current − 0.013 0.871 < 0.001 0.995
Dependent variable: AD-CT
Young adulthood − 0.002 0.970 0.008 0.894
Midlife − 0.017 0.779 − 0.001 0.987
Current − 0.117 0.088 − 0.033 0.586
Adjusted for age, gender, education, apolipoprotein E ε4 status, vascular risk
score, use of sleep pill, Hamilton Depression Rating Score. AD-CT were natural
log-transformed to achieve normal distribution
AD-CM Alzheimer’s disease signature region cerebral glucose metabolism, AD-
CT Alzheimer’s disease signature region cortical thickness
aPositive beta value means that better sleep quality or decreased duration of
sleep is associated with decreased glucose metabolism and/or cortical
thickness, respectively
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present study, additional analyses were performed asses-
sing the previously identified brain regions, including the
OFC, superior frontal cortex, and insula, but no significant
associations were observed (Additional file 1: Table S2).
These discrepancies may be related to the differences in
subject characteristics and analysis methods among stud-
ies. Although the present study included only elderly
participants, previous studies [9, 15, 40, 41] included a
wide range of ages with a younger average age. Because
normal aging itself influences atrophy in the prefrontal
cortex, including the OFC [42], our negative results can
be interpreted to mean that the association between poor
sleep and brain atrophy was relatively diminished due to
the aging effects in elderly individuals. Another possibility
for this discrepancy could be the use of different image
analysis methods; we employed an ROI-based approach
whereas previous studies [9, 15, 40, 41] have used voxel-
based methods.
The strengths of the present study include the evalu-
ation of sleep experiences in different lifetime periods,
the use of multimodal neuroimaging, and the recruit-
ment of healthy elderly people with fewer depressive
symptoms and few sleep disorders. However, several
limitations should also be mentioned. First, we included
only subjective measurements of sleep experiences and
did not employ objective sleep measures. However, there
is a modest relationship between self-reported sleep
experiences and more objective measures using poly-
somnography [21, 43]. Apart from its relevance to the
objectively measured sleep, self-reported sleep experi-
ences are important because they are strongly associated
with the risk for AD dementia [3] and Aβ burden [8–11],
which was also observed in the present study. Further-
more, sleep questionnaires are advantageous in that they
are feasible, easily used in clinical practice, and directly
reflect one’s perception of their own sleep, which may
incorporate their actual sleep patterns as well as the emo-
tional response to sleep [44, 45]. Second, although all
efforts were made to overcome the limitations inherent to
cross-sectional studies and the lifetime sleep experiences
were separately assessed over three periods of life, all data
on sleep experiences were obtained based on individual
recall. The recall bias of sleep assessment increases with
poor cognitive function [46] and severe depressive symp-
tom [47]. To reduce this bias as much as possible, only
CN elderly subjects without depressive disorders were
included in this study. As a result, the overall age-related
pattern of self-reported sleep in the present subjects
(Table 1) matched well with the established age-related
pattern of sleep based on objective measurement, i.e.,
sleep quality got poorer and sleep duration became
shorter as the age of the participants increased [48]. If
recall bias occurs randomly, then it is likely that the rela-
tionships between sleep and the biomarkers of AD were
underestimated. Therefore, our positive findings were not
likely to be observed by chance. Finally, it is possible that
the bad sleep experiences were related to other unmeas-
ured etiological factors, such as poor sleep hygiene,
psychological factors, and/or other subclinical medical
conditions, which in and of themselves may be linked to
AD processes.
Conclusions
Our results suggest that bad sleep quality during midlife
increases pathological Aβ deposition in the brain and
that short sleep duration during the same period acceler-
ates AD-related regional hypometabolism. On the other
hand, the present results do not support the hypothesis
that Aβ deposition or the neurodegenerative process
influences sleep experiences in cognitively healthy old
adults.
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